Ray McDermott

38.4k total citations · 6 hit papers
241 papers, 8.9k citations indexed

About

Ray McDermott is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ray McDermott has authored 241 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Pulmonary and Respiratory Medicine, 127 papers in Oncology and 42 papers in Surgery. Recurrent topics in Ray McDermott's work include Prostate Cancer Treatment and Research (64 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Colorectal Cancer Treatments and Studies (33 papers). Ray McDermott is often cited by papers focused on Prostate Cancer Treatment and Research (64 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Colorectal Cancer Treatments and Studies (33 papers). Ray McDermott collaborates with scholars based in Ireland, United States and France. Ray McDermott's co-authors include Michael J. Overman, Thierry André, Scott Kopetz, Sara Lonardi, Andrew Hill, Rebecca A. Moss, Heinz‐Josef Lenz, Z. Alexander Cao, Jean-Marie Ledeine and Michael A. Morse and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ray McDermott

231 papers receiving 8.7k citations

Hit Papers

Nivolumab in patients wit... 2012 2026 2016 2021 2017 2018 2020 2017 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
    2017 2.0k citations Michael J. Overman, Ray McDermott et al. profile →
  2. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
    2018 1.4k citations Michael J. Overman, Sara Lonardi et al. Journal of Clinical Oncology profile →
  3. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
    2020 498 citations Thomas Powles, Elizabeth R. Plimack et al. profile →
  4. Circular RNAs: Biogenesis, Function and Role in Human Diseases
    2017 442 citations Anne‐Marie Baird, Ray McDermott et al. profile →
  5. Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
    2012 377 citations Ray McDermott, William Watson et al. profile →
  6. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
    2022 154 citations Thierry André, Sara Lonardi et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ray McDermott 5.2k 2.7k 2.3k 2.1k 1.8k 241 8.9k
Gerrit‐Jan Liefers 5.2k 1.0× 1.7k 0.6× 1.3k 0.6× 2.8k 1.3× 1.4k 0.7× 243 9.0k
Bert H. O’Neil 5.7k 1.1× 2.0k 0.7× 2.5k 1.1× 1.3k 0.6× 1.3k 0.7× 255 9.1k
Anthony Elias 5.9k 1.1× 3.5k 1.3× 2.2k 0.9× 2.0k 0.9× 1.1k 0.6× 205 9.8k
David Khayat 5.3k 1.0× 2.6k 1.0× 2.4k 1.0× 1.4k 0.7× 1.2k 0.7× 108 8.4k
Bhumsuk Keam 6.1k 1.2× 4.0k 1.5× 2.1k 0.9× 1.6k 0.7× 981 0.5× 373 9.9k
Fausto Petrelli 5.9k 1.1× 3.2k 1.2× 1.3k 0.6× 1.7k 0.8× 1.2k 0.7× 280 9.1k
Martee L. Hensley 4.2k 0.8× 4.7k 1.7× 1.8k 0.8× 1.1k 0.5× 1.5k 0.8× 223 13.3k
Paul Ruff 6.4k 1.2× 2.6k 1.0× 1.4k 0.6× 1.2k 0.6× 1.8k 1.0× 155 8.9k
Christos S. Karapetis 8.2k 1.6× 3.8k 1.4× 2.0k 0.9× 2.3k 1.1× 2.8k 1.5× 314 11.2k
Carol Aghajanian 6.1k 1.2× 2.6k 1.0× 3.6k 1.6× 1.4k 0.7× 1.7k 0.9× 425 15.3k

Countries citing papers authored by Ray McDermott

Since Specialization
Citations

This map shows the geographic impact of Ray McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray McDermott more than expected).

Fields of papers citing papers by Ray McDermott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray McDermott. The network helps show where Ray McDermott may publish in the future.

Co-authorship network of co-authors of Ray McDermott

This figure shows the co-authorship network connecting the top 25 collaborators of Ray McDermott. A scholar is included among the top collaborators of Ray McDermott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ray McDermott. Ray McDermott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hong, David S., Rui‐Hua Xu, Miranda P. Dierselhuis, et al.. (2025). Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Open. 10(6). 105110–105110. 1 indexed citations
3.
McDermott, Ray, et al.. (2024). Late side effects of testicular cancer and treatment: a comprehensive review. Discover Oncology. 15(1). 646–646. 2 indexed citations
4.
Shore, Neal D., Joan Carles, Ray McDermott, Neeraj Agarwal, & Bertrand Tombal. (2024). Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Frontiers in Medicine. 11. 1460212–1460212. 1 indexed citations
5.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505. 8 indexed citations
6.
Khan, Manoranjan, et al.. (2024). Long term sequelae of testicular cancer and treatment: A point prevalence observational study.. Journal of Clinical Oncology. 42(16_suppl). e17015–e17015. 1 indexed citations
7.
Cabanillas, Maria E., Marcia S. Brose, Ray McDermott, et al.. (2024). Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).. Journal of Clinical Oncology. 42(16_suppl). 6095–6095. 4 indexed citations
8.
Davis, Ian D., Robert Zielinski, Alastair Thomson, et al.. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. Journal of Clinical Oncology. 42(16_suppl). 5079–5079. 3 indexed citations
9.
Keane, Fergus, Richard Tuli, Catherine O’Connor, et al.. (2024). Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights.. Journal of Clinical Oncology. 42(16_suppl). 4174–4174.
10.
McDermott, Ray, et al.. (2024). A systematic review of whether Health Impact Assessment frameworks support best practice principles. Public Health. 233. 137–144. 6 indexed citations
11.
12.
Punt, Cornelis J.A., Volker Heinemann, Tim Maughan, et al.. (2023). Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. ESMO Open. 8(2). 101199–101199. 4 indexed citations
13.
Drilon, Alexander, Lin Shen, François Doz, et al.. (2023). 668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer. Annals of Oncology. 34. S470–S470. 2 indexed citations
14.
Horvath, Lisa G., Ian D. Davis, Andrew Martin, et al.. (2023). 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Annals of Oncology. 34. S968–S969. 2 indexed citations
15.
Hong, David S., Ray McDermott, Lin Shen, et al.. (2023). 667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. Annals of Oncology. 34. S469–S469. 3 indexed citations
16.
Moran, Bruce, Anne‐Marie Baird, Colm J. O’Rourke, et al.. (2021). Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. Clinical Epigenetics. 13(1). 168–168. 19 indexed citations
17.
Rini, Brian I., Michael B. Atkins, Elizabeth R. Plimack, et al.. (2021). Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European Urology Oncology. 5(2). 225–234. 25 indexed citations
18.
McDermott, Ray, Emmanuel S. Antonarakis, Christopher Hoimes, et al.. (2020). KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). European Urology Open Science. 19. e885–e886. 2 indexed citations
19.
Overman, Michael J., Sara Lonardi, Ka Yeung Mark Wong, et al.. (2018). Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer. Journal of Clinical Oncology. 36(8). 773–779. 1429 indexed citations breakdown →
20.
Atkins, Michael B., F. Stephen Hodi, John A. Thompson, et al.. (2018). Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research. 24(8). 1805–1815. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerrit‐Jan Liefers Breakdown of academic impact, for papers by Bert H. O’Neil Breakdown of academic impact, for papers by Anthony Elias Breakdown of academic impact, for papers by David Khayat Breakdown of academic impact, for papers by Bhumsuk Keam Breakdown of academic impact, for papers by Fausto Petrelli Breakdown of academic impact, for papers by Martee L. Hensley Breakdown of academic impact, for papers by Paul Ruff Breakdown of academic impact, for papers by Christos S. Karapetis Breakdown of academic impact, for papers by Carol Aghajanian
Rankless by CCL
2026